Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
EDIT

Editas Medicine

$29.80

0.7 (2.41%)

16:05
08/16/18
08/16
16:05
08/16/18
16:05
Hot Stocks
Editas Medicine announces completion of recombinant DNA committee registration »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

SMMT

Summit Therapeutics

$2.06

-0.2 (-8.85%)

07:07
08/16/18
08/16
07:07
08/16/18
07:07
Hot Stocks
Summit Therapeutics awarded additional $12M in contract with BARDA »

Summit Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
ESRX

Express Scripts

$86.05

2.01 (2.39%)

, BMRN

BioMarin

$103.17

0.46 (0.45%)

07:46
08/15/18
08/15
07:46
08/15/18
07:46
Periodicals
Express Scripts in talks with biotechs for hemophilia therapies, Reuters reports »

Express Scripts (ESRX) is…

ESRX

Express Scripts

$86.05

2.01 (2.39%)

BMRN

BioMarin

$103.17

0.46 (0.45%)

ONCE

Spark Therapeutics

$61.35

2.84 (4.85%)

BLUE

Bluebird Bio

$156.25

0.2 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 10

    Sep

  • 12

    Sep

  • 01

    Dec

DRNA

Dicerna

$14.85

0.08 (0.54%)

07:25
08/15/18
08/15
07:25
08/15/18
07:25
Upgrade
Dicerna rating change at H.C. Wainwright »

Dicerna upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Monday
RGNX

Regenxbio

$67.35

0.55 (0.82%)

07:26
08/13/18
08/13
07:26
08/13/18
07:26
Recommendations
Regenxbio analyst commentary at Barclays »

Regenxbio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
MRUS

Merus

$19.03

-0.84 (-4.23%)

08:41
08/10/18
08/10
08:41
08/10/18
08:41
Earnings
Merus reports Q2 EPS (EUR0.20) vs. (EUR1.01) last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

RGNX

Regenxbio

$66.80

-3.8 (-5.38%)

07:36
08/10/18
08/10
07:36
08/10/18
07:36
Syndicate
Regenxbio 2.7M share Secondary priced at $65.00 »

Morgan Stanley,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

CBAY

CymaBay

$11.66

-0.01 (-0.09%)

19:22
08/09/18
08/09
19:22
08/09/18
19:22
Recommendations
CymaBay analyst commentary at Piper Jaffray »

CymaBay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

  • 14

    Aug

CBAY

CymaBay

$11.63

-0.04 (-0.34%)

16:03
08/09/18
08/09
16:03
08/09/18
16:03
Earnings
CymaBay reports Q2 EPS (30c), consensus (25c) »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

  • 14

    Aug

EDIT

Editas Medicine

$29.00

1.36 (4.92%)

09:59
08/09/18
08/09
09:59
08/09/18
09:59
Conference/Events
Editas Medicine management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.